Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults
Not Applicable
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Other: BPTOther: NP
- Registration Number
- NCT02518204
- Lead Sponsor
- Lumos Labs, Inc.
- Brief Summary
The purpose of this study is to evaluate the concurrent validity between the Brain Performance Test (BPT) subtests and corresponding conventional in-person neuropsychological assessments (NP).
- Detailed Description
This will be a multi-site, randomized, counterbalanced, two-period, two-sequence, validation study of the online, unsupervised Brain Performance Test (BPT). Over the course of 14 days, participants will complete two in-clinic visits during which they will complete both the BPT and in-person neuropsychological assessments (NP).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 229
Inclusion Criteria
- Native English speaker
- Capable and willing to provide informed consent
- Able to use a computer and mouse without assistance
- Limited (< 3 days) or no experience with Lumosity.com
- Limited (< 3 days) or no experience with other cognitive training programs (e.g., FitBrains, CogMed)
- Willing to refrain from online cognitive training during the course of the study
- No recent (<1 years) experience with either computer-based or in-person neuropsychological tests (e.g., WAIS-IV, WISC, Halstead-Reitan Battery, MATRICS, CogState, CNS Vital Signs)
- Good general health assessed via self-reported online physical questionnaire and medical history questionnaire
Exclusion Criteria
- Illiterate or unable to understand written English sufficiently to comprehend study instructions and consent form
- Uncorrected visual impairment (beyond that required to qualify for a California Driver's License) that may impact the ability to complete assessments (self-report or determined by the clinician)
- Uncorrected auditory impairment that may impact the ability to complete assessments (self-report or determined by the clinician)
- Self-reported clinical diagnosis for primary psychiatric or neurological disorder (e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder, Parkinson's disease, epilepsy)
- Self-reported history of concussion or traumatic brain injury, that is considered clinically significant in the opinion of the investigator (e.g. loss of consciousness ≤ 30 minutes)
- Self-reported diagnosis of mental retardation or pervasive developmental disorder
- Self-reported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other dementia
- Self-reported history of sustained substance or alcohol abuse or dependence, that is considered clinically significant in the opinion of the investigator (e.g. as defined by DSM-5)
- Self-report that subject is currently taking an antipsychotic, antidepressant, anti-anxiety, or a cognitively-enhancing medication (e.g. Ritalin), or in the last 72 hours, narcotics for pain or other medications that may impact cognitive performance (e.g. sleeping medications/aides or cold/allergy medications)
- Any other significant medical condition that could impact cognitive performance or result in cognitive impairment in the opinion of the investigator
- Score <28 on the MMSE
- Positive urine test for recent substance use on either testing day
- Breath Alcohol Content of 0.01% or greater on either testing day
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BPT, NP NP Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments NP, BPT BPT Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery BPT, NP BPT Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments NP, BPT NP Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
- Primary Outcome Measures
Name Time Method Correlation coefficients (Pearson's r) of scaled scores of BPT subtests compared to scaled scores of their NP correlates at Time 1 1 day
- Secondary Outcome Measures
Name Time Method Interclass correlations (ICC) of scaled scores of BPT subtests compared to scaled scores of their NP correlates at Time 1 1 day Correlation coefficients (Pearson's r and ICC) of BPT Grand Index and NP Overall Index at Time 1 and Time 2 as measures of reliability 2 weeks Correlation coefficients (Pearson's r and ICC) of raw and scaled scores of BPT subtests at Time 1 and Time 2 as measures of test-retest reliability 2 weeks Correlation coefficients (Pearson's r and ICC) of raw scores of BPT subtests compared to raw scores of their NP correlates at Time 1 1 day Correlation coefficients (Pearson's r and ICC) of BPT composite indices and NP composite indices at Time 1 1 day Correlation coefficients (Pearson's r and ICC) of composite indices of BPT and NP at Time 1 and Time 2 as measures of reliability 2 weeks
Trial Locations
- Locations (3)
Orange County Research Center
🇺🇸Garden Grove, California, United States
Northern California Research Center
🇺🇸Oakland, California, United States
South Bay Research Center
🇺🇸Torrance, California, United States